SEARCH:   Advanced

Blood, 1 October 2007, Vol. 110, No. 7, pp. 2342-2350. Prepublished online as a Blood First Edition Paper on September 14, 2007; DOI 10.1182/blood-2007-01-065573. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-01-065573v1 blood-2007-01-065573v2 110/7/2342    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Goel, A. Articles by Russell, S. J. Search for Related Content PubMed PubMed Citation Articles by Goel, A. Articles by Russell, S. J. Related Collections Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  GENE THERAPY Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene Apollina Goel1, Stephanie K. Carlson1,2, Kelly L. Classic3, Suzanne Greiner1, Shruthi Naik1, Anthony T. Power4, John C. Bell4, and Stephen J. Russell1 1 Molecular Medicine Program 2 Division of Radiation Oncology, Department of Radiology 3 Section of Safety, Mayo Clinic College of Medicine, Rochester, MN; and 4 Ottawa Health Research Institute, University of Ottawa, Canada Multiple myeloma is a radiosensitive malignancy that is currently incurable. Here, we generated a novel recombinant vesicular stomatitis virus [VSV(51)-NIS] that has a deletion of methionine 51 in the matrix protein and expresses the human sodium iodide symporter (NIS) gene. VSV(51)-NIS showed specific oncolytic activity against myeloma cell lines and primary myeloma cells and was able to replicate to high titers in myeloma cells in vitro. Iodide uptake assays showed accumulation of radioactive iodide in VSV(51)-NIS–infected myeloma cells that was specific to the function of the NIS transgene. In bg/nd/xid mice with established subcutaneous myeloma tumors, administration of VSV(51)-NIS resulted in high intratumoral virus replication and tumor regression. VSV-associated neurotoxicity was not observed. Intratumoral spread of the infection was monitored noninvasively by serial gamma camera imaging of 123I-iodide biodistribution. Dosimetry calculations based on these images pointed to the feasibility of combination radiovirotherapy with VSV(51)-NIS plus 131I. Immunocompetent mice with syngeneic 5TGM1 myeloma tumors (either subcutaneous or orthotopic) showed significant enhancements of tumor regression and survival when VSV(51)-NIS was combined with 131I. These results show that VSV(51)-NIS is a safe oncolytic agent with significant therapeutic potential in multiple myeloma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: I. Peerlinck, A. Merron, P. Baril, S. Conchon, P. Martin-Duque, C. Hindorf, J. Burnet, M. Quintanilla, M. Hingorani, R. Iggo, et al. Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter Clin. Cancer Res., November 1, 2009; 15(21): 6595 - 6601. [Abstract] [Full Text] [PDF] K. Klutz, V. Russ, M. J. Willhauck, N. Wunderlich, C. Zach, F. J. Gildehaus, B. Goke, E. Wagner, M. Ogris, and C. Spitzweg Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene Clin. Cancer Res., October 1, 2009; 15(19): 6079 - 6086. [Abstract] [Full Text] [PDF] T. Hakkarainen, M. Rajecki, M. Sarparanta, M. Tenhunen, A. J. Airaksinen, R. A. Desmond, K. Kairemo, and A. Hemminki Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter Clin. Cancer Res., September 1, 2009; 15(17): 5396 - 5403. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020